Entry - #607628 - EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 11; EIG11 - OMIM
# 607628

EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 11; EIG11


Other entities represented in this entry:

EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 8, INCLUDED; EJM8, INCLUDED
EPILEPSY, JUVENILE ABSENCE, SUSCEPTIBILITY TO, 2, INCLUDED; EJA2, INCLUDED

Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
3q27.1 {Epilepsy, juvenile absence, susceptibility to, 2} 607628 AD 3 CLCN2 600570
3q27.1 {Epilepsy, juvenile myoclonic, susceptibility to, 8} 607628 AD 3 CLCN2 600570
3q27.1 {Epilepsy, idiopathic generalized, susceptibility to, 11} 607628 AD 3 CLCN2 600570
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
NEUROLOGIC
Central Nervous System
- Generalized tonic-clonic seizures (GTCS) on awakening
- GTCS during 'leisure' time (evening)
- Myoclonic seizures may occur
- Absence seizures may occur
MISCELLANEOUS
- Variable age of onset (6 to 35 years)
- Precipitated by sleep deprivation
MOLECULAR BASIS
- Caused by mutation in the chloride channel-2 gene (CLCN2, 600570.0001)
Epilepsy, myoclonic juvenile - PS254770 - 17 Entries
Epilepsy, idiopathic generalized - PS600669 - 29 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.33 {Epilepsy, idiopathic generalized, 10} AD 3 613060 GABRD 137163
1p36.33 {Generalized epilepsy with febrile seizures plus, type 5, susceptibility to} AD 3 613060 GABRD 137163
1p36.33 {Epilepsy, juvenile myoclonic, susceptibility to} AD 3 613060 GABRD 137163
1p34.2 {Epilepsy, idiopathic generalized, susceptibility to, 12} AD 3 614847 SLC2A1 138140
2q23.3 {Epilepsy, juvenile myoclonic, susceptibility to, 6} AD 3 607682 CACNB4 601949
2q23.3 {Epilepsy, idiopathic generalized, susceptibility to, 9} AD 3 607682 CACNB4 601949
3q13.33-q21.1 {?Epilepsy idiopathic generalized, susceptibility to, 8} AD 3 612899 CASR 601199
3q27.1 {Epilepsy, idiopathic generalized, susceptibility to, 11} AD 3 607628 CLCN2 600570
3q27.1 {Epilepsy, juvenile absence, susceptibility to, 2} AD 3 607628 CLCN2 600570
3q27.1 {Epilepsy, juvenile myoclonic, susceptibility to, 8} AD 3 607628 CLCN2 600570
5q34 {Epilepsy, childhood absence, susceptibility to, 4} 3 611136 GABRA1 137160
5q34 {Epilepsy, juvenile myoclonic, susceptibility to, 5} 3 611136 GABRA1 137160
8q24 {Epilepsy, idiopathic generalized, susceptibility to, 1} AD 2 600669 EIG1 600669
9q21.13 {Epilepsy, idiopathic generalized, susceptibility to, 15} AD 3 618357 RORB 601972
9q32-q33 {Epilepsy, idiopathic generalized, susceptibility to, 3} AR 2 608762 EIG3 608762
10p11.22 {Epilepsy, idiopathic generalized, susceptibility to, 5} 2 611934 EIG5 611934
10q22.3 {Epilepsy, idiopathic generalized, susceptibility to, 16} AD 3 618596 KCNMA1 600150
10q25-q26 {Epilepsy, idiopathic generalized, susceptibility to 4} 2 609750 EIG4 609750
14q23 {Epilepsy, idiopathic generalized, susceptibility to, 2} 2 606972 EIG2 606972
15q14 Epilepsy, juvenile myoclonic IC 2 604827 EIG7 604827
15q14 {Epilepsy, idiopathic generalized, susceptibility to, 7} IC 2 604827 EIG7 604827
15q24.1 {Epilepsy, idiopathic generalized, susceptibility to, 18} AD 3 619521 HCN4 605206
16p13.3 {Epilepsy, childhood absence, susceptibility to, 6} 3 611942 CACNA1H 607904
16p13.3 {Epilepsy, idiopathic generalized, susceptibility to, 6} 3 611942 CACNA1H 607904
19p13.3 Febrile seizures, familial, 2 AD 2 602477 FEB2 602477
19p13.3 Generalized epilepsy with febrile seizures plus, type 11 AD 3 602477 HCN2 602781
19p13.3 {Epilepsy, idiopathic generalized, susceptibility to, 17} AD 3 602477 HCN2 602781
19p13.3 Febrile seizures, familial, 2 AD 3 602477 HCN2 602781
20q13.12 {Epilepsy, idiopathic generalized, susceptibility to, 14} AD 3 616685 SLC12A5 606726
Epilepsy, juvenile absence - PS607631 - 4 Entries

TEXT

A number sign (#) is used with this entry because some evidence has suggested that susceptibility to idiopathic generalized epilepsy-11 (EIG11), juvenile myoclonic epilepsy-8 (EJM8), and juvenile absence epilepsy-2 (EJA2) may be conferred by variation in the chloride channel-2 gene (CLCN2; 600570) on chromosome 3q27. However, there has been some controversy over whether variation in the CLCN2 gene has a role in epilepsy (see MOLECULAR GENETICS).


Description

Both juvenile myoclonic epilepsy and juvenile absence epilepsy are subtypes of idiopathic generalized epilepsy (EIG).

For a general phenotypic description and a discussion of genetic heterogeneity of these disorders, see EIG1 (600669), EJM1 (254770), and EJA1 (607631).


Mapping

Sander et al. (2000) used nonparametric multipoint linkage analysis to identify susceptibility loci among 130 IGE-multiplex families ascertained through a proband with childhood or juvenile absence epilepsy or juvenile myoclonic epilepsy, and 1 or more sibs affected by an IGE trait. They obtained evidence for a novel IGE susceptibility locus on chromosome 3q26 with a peak nonparametric linkage (NPL) score of 4.19 at D3S3725 (p = 0.000017).


Molecular Genetics

In 2 sibs with juvenile absence epilepsy found by Sander et al. (2000) to be linked to chromosome 3q26, Haug et al. (2003) identified a heterozygous mutation in the CLCN2 gene (G715E; 600570.0003). Another sib with generalized spike-wave discharges on EEG also carried the mutation. The father, who also carried the mutation, reportedly had unclassified seizures in childhood, but his severe alcoholism as an adult rendered his disease status uncertain. Functional studies of the mutant channel showed normal current amplitudes, but altered voltage-dependent gating, potentially leading to hyperexcitability. The family structure, diagnosis, and mutation status were confirmed by Kleefuss-Lie et al. (2009). The mutation was not observed in 4,700 German control individuals.

In 3 of 46 unrelated families with IGE localized to 3q26 (including some of the families reported by Sander et al. (2000)), Haug et al. (2003) identified 3 mutations in the CLCN2 gene (600570.0001-600570.0003). In a reevaluation of 2 of the families, 1 with juvenile myoclonic epilepsy and 1 with childhood absence epilepsy Haug et al. (2003), Kleefuss-Lie et al. (2009) found discrepancies in the family structure, phenotype, and genetic analysis. On this basis, all but one of the original authors retracted the paper.

Niemeyer et al. (2010) disagreed with the conclusion by Kleefuss-Lie et al. (2009) that some of the work by Haug et al. (2003) had merit. Based on lack of functional consequences of the variants reported by Haug et al. (2003) (600570.0001-600570.0003), Niemeyer et al. (2010) asserted that there is no evidence for a role of CLCN2 variants in idiopathic generalized epilepsy.

In 2 sibs of Tunisian origin with juvenile myoclonic epilepsy, Saint-Martin et al. (2009) identified a heterozygous mutation in the CLCN2 gene (R235Q; 600570.0004). Another sib with JME was not available for genetic analysis. The mutation was not observed in 263 control individuals from North Africa or 183 French controls. Saint-Martin et al. (2009) identified a different heterozygous mutation in the CLCN2 gene (R577Q; 600570.0005) in 2 German sibs with idiopathic generalized epilepsy. The mutation was not observed in 203 German controls or 183 French controls. In both families, the unaffected father also had the mutation, suggesting either reduced penetrance or that additional unidentified factors are necessary for full phenotypic expression.


Nomenclature

'ECA3' was previously used to designate the locus on 3q26 for childhood absence epilepsy; this had since been removed since the paper was retracted (Haug et al., 2003).


REFERENCES

  1. Haug, K., Warnstedt, M., Alekov, A. K., Sander, T., Ramirez, A., Poser, B., Maljevic, S., Hebeisen, S., Kubisch, C., Rebstock, J., Horvath, S., Hallmann, K., and 13 others. Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nature Genet. 33: 527-532, 2003. Note: Retraction: Nature Genet. 41: 1043 only, 2009. [PubMed: 12612585, related citations] [Full Text]

  2. Kleefuss-Lie, A., Friedl, W., Cichon, S., Haug, K., Warnstedt, M., Alekov, A., Sander, T., Ramirez, A., Poser, B., Maljevic, S., Hebeisen, S., Kubisch, C., and 15 others. CLCN2 variants in idiopathic generalized epilepsy. (Letter) Nature Genet. 41: 954-955, 2009. [PubMed: 19710712, related citations] [Full Text]

  3. Niemeyer, M. I., Cid, L. P., Sepulveda, F. V., Blanz, J., Auberson, M., Jentsch, T. J. No evidence for a role of CLCN2 variants in idiopathic generalized epilepsy. (Letter) Nature Genet. 42: 3 only, 2010. [PubMed: 20037607, related citations] [Full Text]

  4. Saint-Martin, C., Gauvain, G., Teodorescu, G., Gourfinkel-An, I., Fedirko, E., Weber, Y. G., Maljevic, S., Ernst, J.-P., Garcia-Olivares, J., Fahlke, C., Nabbout, R., LeGuern, E., Lerche, H., Poncer, J. C., Depienne, C. Two novel CLCN2 mutations accelerating chloride channel deactivation are associated with idiopathic generalized epilepsy. Hum. Mutat. 30: 397-405, 2009. [PubMed: 19191339, related citations] [Full Text]

  5. Sander, T., Schulz, H., Saar, K., Gennaro, E., Riggio, M. C., Bianchi, A., Zara, F., Luna, D., Bulteau, C., Kaminska, A., Ville, D., Cieuta, C., and 14 others. Genome search for susceptibility loci of common idiopathic generalised epilepsies. Hum. Molec. Genet. 9: 1465-1472, 2000. [PubMed: 10888596, related citations] [Full Text]


Cassandra L. Kniffin - updated : 1/19/2010
Cassandra L. Kniffin - updated : 10/2/2009
Creation Date:
Cassandra L. Kniffin : 3/14/2003
carol : 09/26/2019
carol : 07/18/2017
carol : 06/13/2016
alopez : 1/28/2010
ckniffin : 1/19/2010
carol : 10/6/2009
ckniffin : 10/2/2009
carol : 4/9/2003
ckniffin : 3/20/2003

# 607628

EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 11; EIG11


Other entities represented in this entry:

EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 8, INCLUDED; EJM8, INCLUDED
EPILEPSY, JUVENILE ABSENCE, SUSCEPTIBILITY TO, 2, INCLUDED; EJA2, INCLUDED

ORPHA: 307;   DO: 0111312;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
3q27.1 {Epilepsy, juvenile absence, susceptibility to, 2} 607628 Autosomal dominant 3 CLCN2 600570
3q27.1 {Epilepsy, juvenile myoclonic, susceptibility to, 8} 607628 Autosomal dominant 3 CLCN2 600570
3q27.1 {Epilepsy, idiopathic generalized, susceptibility to, 11} 607628 Autosomal dominant 3 CLCN2 600570

TEXT

A number sign (#) is used with this entry because some evidence has suggested that susceptibility to idiopathic generalized epilepsy-11 (EIG11), juvenile myoclonic epilepsy-8 (EJM8), and juvenile absence epilepsy-2 (EJA2) may be conferred by variation in the chloride channel-2 gene (CLCN2; 600570) on chromosome 3q27. However, there has been some controversy over whether variation in the CLCN2 gene has a role in epilepsy (see MOLECULAR GENETICS).


Description

Both juvenile myoclonic epilepsy and juvenile absence epilepsy are subtypes of idiopathic generalized epilepsy (EIG).

For a general phenotypic description and a discussion of genetic heterogeneity of these disorders, see EIG1 (600669), EJM1 (254770), and EJA1 (607631).


Mapping

Sander et al. (2000) used nonparametric multipoint linkage analysis to identify susceptibility loci among 130 IGE-multiplex families ascertained through a proband with childhood or juvenile absence epilepsy or juvenile myoclonic epilepsy, and 1 or more sibs affected by an IGE trait. They obtained evidence for a novel IGE susceptibility locus on chromosome 3q26 with a peak nonparametric linkage (NPL) score of 4.19 at D3S3725 (p = 0.000017).


Molecular Genetics

In 2 sibs with juvenile absence epilepsy found by Sander et al. (2000) to be linked to chromosome 3q26, Haug et al. (2003) identified a heterozygous mutation in the CLCN2 gene (G715E; 600570.0003). Another sib with generalized spike-wave discharges on EEG also carried the mutation. The father, who also carried the mutation, reportedly had unclassified seizures in childhood, but his severe alcoholism as an adult rendered his disease status uncertain. Functional studies of the mutant channel showed normal current amplitudes, but altered voltage-dependent gating, potentially leading to hyperexcitability. The family structure, diagnosis, and mutation status were confirmed by Kleefuss-Lie et al. (2009). The mutation was not observed in 4,700 German control individuals.

In 3 of 46 unrelated families with IGE localized to 3q26 (including some of the families reported by Sander et al. (2000)), Haug et al. (2003) identified 3 mutations in the CLCN2 gene (600570.0001-600570.0003). In a reevaluation of 2 of the families, 1 with juvenile myoclonic epilepsy and 1 with childhood absence epilepsy Haug et al. (2003), Kleefuss-Lie et al. (2009) found discrepancies in the family structure, phenotype, and genetic analysis. On this basis, all but one of the original authors retracted the paper.

Niemeyer et al. (2010) disagreed with the conclusion by Kleefuss-Lie et al. (2009) that some of the work by Haug et al. (2003) had merit. Based on lack of functional consequences of the variants reported by Haug et al. (2003) (600570.0001-600570.0003), Niemeyer et al. (2010) asserted that there is no evidence for a role of CLCN2 variants in idiopathic generalized epilepsy.

In 2 sibs of Tunisian origin with juvenile myoclonic epilepsy, Saint-Martin et al. (2009) identified a heterozygous mutation in the CLCN2 gene (R235Q; 600570.0004). Another sib with JME was not available for genetic analysis. The mutation was not observed in 263 control individuals from North Africa or 183 French controls. Saint-Martin et al. (2009) identified a different heterozygous mutation in the CLCN2 gene (R577Q; 600570.0005) in 2 German sibs with idiopathic generalized epilepsy. The mutation was not observed in 203 German controls or 183 French controls. In both families, the unaffected father also had the mutation, suggesting either reduced penetrance or that additional unidentified factors are necessary for full phenotypic expression.


Nomenclature

'ECA3' was previously used to designate the locus on 3q26 for childhood absence epilepsy; this had since been removed since the paper was retracted (Haug et al., 2003).


REFERENCES

  1. Haug, K., Warnstedt, M., Alekov, A. K., Sander, T., Ramirez, A., Poser, B., Maljevic, S., Hebeisen, S., Kubisch, C., Rebstock, J., Horvath, S., Hallmann, K., and 13 others. Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nature Genet. 33: 527-532, 2003. Note: Retraction: Nature Genet. 41: 1043 only, 2009. [PubMed: 12612585] [Full Text: https://doi.org/10.1038/ng1121]

  2. Kleefuss-Lie, A., Friedl, W., Cichon, S., Haug, K., Warnstedt, M., Alekov, A., Sander, T., Ramirez, A., Poser, B., Maljevic, S., Hebeisen, S., Kubisch, C., and 15 others. CLCN2 variants in idiopathic generalized epilepsy. (Letter) Nature Genet. 41: 954-955, 2009. [PubMed: 19710712] [Full Text: https://doi.org/10.1038/ng0909-954]

  3. Niemeyer, M. I., Cid, L. P., Sepulveda, F. V., Blanz, J., Auberson, M., Jentsch, T. J. No evidence for a role of CLCN2 variants in idiopathic generalized epilepsy. (Letter) Nature Genet. 42: 3 only, 2010. [PubMed: 20037607] [Full Text: https://doi.org/10.1038/ng0110-3]

  4. Saint-Martin, C., Gauvain, G., Teodorescu, G., Gourfinkel-An, I., Fedirko, E., Weber, Y. G., Maljevic, S., Ernst, J.-P., Garcia-Olivares, J., Fahlke, C., Nabbout, R., LeGuern, E., Lerche, H., Poncer, J. C., Depienne, C. Two novel CLCN2 mutations accelerating chloride channel deactivation are associated with idiopathic generalized epilepsy. Hum. Mutat. 30: 397-405, 2009. [PubMed: 19191339] [Full Text: https://doi.org/10.1002/humu.20876]

  5. Sander, T., Schulz, H., Saar, K., Gennaro, E., Riggio, M. C., Bianchi, A., Zara, F., Luna, D., Bulteau, C., Kaminska, A., Ville, D., Cieuta, C., and 14 others. Genome search for susceptibility loci of common idiopathic generalised epilepsies. Hum. Molec. Genet. 9: 1465-1472, 2000. [PubMed: 10888596] [Full Text: https://doi.org/10.1093/hmg/9.10.1465]


Contributors:
Cassandra L. Kniffin - updated : 1/19/2010
Cassandra L. Kniffin - updated : 10/2/2009

Creation Date:
Cassandra L. Kniffin : 3/14/2003

Edit History:
carol : 09/26/2019
carol : 07/18/2017
carol : 06/13/2016
alopez : 1/28/2010
ckniffin : 1/19/2010
carol : 10/6/2009
ckniffin : 10/2/2009
carol : 4/9/2003
ckniffin : 3/20/2003